Bad blood: secrets and lies in a Silicon Valley startup
(Book)
Author:
Status:
Eva H. Perry Regional - Adult Non-Fiction has 3
338.7 CARRE
Fuquay-Varina Community - Adult Non-Fiction
338.7 CARRE
Leesville Community - Adult Non-Fiction
338.7 CARRE
Copies
Location
Call Number
Status
Cary Regional - Adult Non-Fiction
338.7 CARRE
Checked out
Duraleigh Road - Adult Non-Fiction
338.7 CARRE
Checked out
Eva H. Perry Regional - Adult Non-Fiction
338.7 CARRE
On Shelf
Eva H. Perry Regional - Adult Non-Fiction
338.7 CARRE
On Shelf
Eva H. Perry Regional - Adult Non-Fiction
338.7 CARRE
On Shelf
Fuquay-Varina Community - Adult Non-Fiction
338.7 CARRE
On Shelf
Leesville Community - Adult Non-Fiction
338.7 CARRE
On Shelf
Morrisville Community - Adult Non-Fiction
338.7 CARRE
On Shelf
North Regional - Adult Non-Fiction
338.7 CARRE
On Shelf
North Regional - Adult Non-Fiction
338.7 CARRE
On Shelf
North Regional - Adult Non-Fiction
338.7 CARRE
On Shelf
Oberlin Regional - Adult Non-Fiction
338.7 CARRE
On Shelf
Oberlin Regional - Adult Non-Fiction
338.7 CARRE
On Shelf
Oberlin Regional - Adult Non-Fiction
338.7 CARRE
On Shelf
Oberlin Regional - Adult Non-Fiction
338.7 CARRE
Checked out
Oberlin Regional - Adult Non-Fiction
338.7 CARRE
On Shelf
Richard B Harrison - Adult Non-Fiction
338.7 CARRE
On Shelf
Richard B Harrison - Adult Non-Fiction
338.7 CARRE
On Shelf
West Regional - Adult Non-Fiction
338.7 CARRE
On Shelf
West Regional - Adult Non-Fiction
338.7 CARRE
Checked out
More Details
Published:
New York : Alfred A. Knopf, 2018.
Format:
Book
Edition:
First edition.
Physical Desc:
x, 339 pages ; 24 cm
Language:
English
ISBN:
9780525431992, 9780525431992, 9781524731656, 152473165X, 9781524731656
Notes
General Note
"This is a Borzoi book."
Bibliography
Includes bibliographical references and index.
Description
"In 2014 Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup 'unicorn' promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier ... There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When [the author], working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both [he] and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"--,Provided by publisher.
Reviews from GoodReads
Loading GoodReads Reviews.
Citations
APA Citation (style guide)
Carreyrou, J. (2018). Bad blood: secrets and lies in a Silicon Valley startup. First edition. New York, Alfred A. Knopf.
Chicago / Turabian - Author Date Citation (style guide)Carreyrou, John. 2018. Bad Blood: Secrets and Lies in a Silicon Valley Startup. New York, Alfred A. Knopf.
Chicago / Turabian - Humanities Citation (style guide)Carreyrou, John, Bad Blood: Secrets and Lies in a Silicon Valley Startup. New York, Alfred A. Knopf, 2018.
MLA Citation (style guide)Carreyrou, John. Bad Blood: Secrets and Lies in a Silicon Valley Startup. First edition. New York, Alfred A. Knopf, 2018.
Note! Citation formats are based on standards as of July 2022. Citations contain only title, author, edition, publisher, and year published. Citations should be used as a guideline and should be double checked for accuracy.
Staff View
Grouped Work ID:
baef1559-c66a-350a-94da-a1c38154f67e
Record Information
| Last Horizon Extract Time | Apr 21, 2024 03:25:59 PM |
|---|---|
| Last File Modification Time | Apr 22, 2024 03:10:58 AM |
| Last Grouped Work Modification Time | Apr 26, 2024 03:07:59 AM |
MARC Record
| LEADER | 04507pam a2200709 i 4500 | ||
|---|---|---|---|
| 001 | 2018000263 | ||
| 003 | DLC | ||
| 005 | 20200525155700.0 | ||
| 008 | 180316s2018 nyu b 001 0 eng d | ||
| 010 | |a 2018000263 | ||
| 020 | |a 9780525431992|q (pbk.) | ||
| 020 | |a 9780525431992 | ||
| 020 | |a 9781524731656|c $27.95 | ||
| 020 | |a 152473165X|c $27.95 | ||
| 020 | |a 9781524731656|q (hbk.) | ||
| 035 | |a (OCoLC)1029779381 | ||
| 040 | |a DLC|b eng|e rda|c DLC|d TnLvILS | ||
| 042 | |a pcc | ||
| 043 | |a n-us--- | ||
| 050 | 0 | 0 | |a HD9995.H423|b U627 2018 |
| 082 | 0 | 0 | |a 338.7/681761|2 23 |
| 092 | |a 338.7 CARRE | ||
| 100 | 1 | |a Carreyrou, John|e author. | |
| 245 | 1 | 0 | |a Bad blood :|b secrets and lies in a Silicon Valley startup /|c John Carreyrou. |
| 250 | |a First edition. | ||
| 264 | 1 | |a New York :|b Alfred A. Knopf,|c 2018. | |
| 300 | |a x, 339 pages ;|c 24 cm | ||
| 336 | |a text|b txt|2 rdacontent | ||
| 337 | |a unmediated|b n|2 rdamedia | ||
| 338 | |a volume|b nc|2 rdacarrier | ||
| 500 | |a "This is a Borzoi book." | ||
| 504 | |a Includes bibliographical references and index. | ||
| 520 | |a "In 2014 Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup 'unicorn' promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier ... There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When [the author], working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both [he] and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"--|c Provided by publisher. | ||
| 610 | 2 | 0 | |a Theranos (Firm)|x History. |
| 650 | 0 | |a Hematologic equipment industry|z United States. | |
| 650 | 0 | |a Fraud|z United States | |
| 939 | |a ODC|b COM3625689BT|c 2 | ||
| 949 | |b 32046815616888|c SYSANFI|d 338.7 CARRE|l CRY|n 6672660|o 0|s o|w 05/25/2018|x 33|y BK | ||
| 949 | |b 32046819636361|c SYSANFI|d 338.7 CARRE|l DUR|n 7275833|o 0|s o|w 01/02/2020|x 9|y PBK | ||
| 949 | |b 32046819636478|c SYSANFI|d 338.7 CARRE|l EVA|n 7275844|o 0|s i|w 01/02/2020|x 12|y PBK | ||
| 949 | |b 32046815616946|c SYSANFI|d 338.7 CARRE|l EVA|n 6672664|o 0|s i|w 05/25/2018|x 33|y BK | ||
| 949 | |b 32046817612257|c SYSANFI|d 338.7 CARRE|l EVA|n 6981369|o 0|s i|w 03/22/2019|x 19|y BK | ||
| 949 | |b 32046815616789|c SYSANFI|d 338.7 CARRE|l FUQ|n 6672650|o 0|s i|w 05/25/2018|x 25|y BK | ||
| 949 | |b 32046817612232|c SYSANFI|d 338.7 CARRE|l LEE|n 6981367|o 0|s i|w 03/22/2019|x 12|y BK | ||
| 949 | |b 32046817612224|c SYSANFI|d 338.7 CARRE|l MOR|n 6981366|o 0|s i|w 03/22/2019|x 20|y BK | ||
| 949 | |b 32046303273705|c SYSANFI|d 338.7 CARRE|l NOR|n 7989988|o 0|s i|w 04/26/2022|x 1|y BK | ||
| 949 | |b 32046815617035|c SYSANFI|d 338.7 CARRE|l NOR|n 6672673|o 0|s i|w 05/25/2018|x 18|y BK | ||
| 949 | |b 32046819636445|c SYSANFI|d 338.7 CARRE|l NOR|n 7275841|o 0|s i|w 01/02/2020|x 7|y PBK | ||
| 949 | |b 32046815617092|c SYSANFI|d 338.7 CARRE|l OBR|n 6672679|o 0|s i|w 05/25/2018|x 25|y BK | ||
| 949 | |b 32046815616813|c SYSANFI|d 338.7 CARRE|l OBR|n 6672653|o 1|s l|w 05/25/2018|x 21|y BK | ||
| 949 | |b 32046815616904|c SYSANFI|d 338.7 CARRE|l OBR|n 6672662|o 0|s o|w 05/25/2018|x 31|y BK | ||
| 949 | |b 32046815616870|c SYSANFI|d 338.7 CARRE|l OBR|n 6672659|o 0|s i|w 05/25/2018|x 32|y BK | ||
| 949 | |b 32046815616763|c SYSANFI|d 338.7 CARRE|l OBR|n 6672648|o 1|s l|w 05/25/2018|x 32|y BK | ||
| 949 | |b 32046815616862|c SYSANFI|d 338.7 CARRE|l OBR|n 6672658|o 1|s l|w 05/25/2018|x 25|y BK | ||
| 949 | |b 32046819636536|c SYSANFI|d 338.7 CARRE|l OBR|n 7275850|o 0|s i|w 01/02/2020|x 12|y PBK | ||
| 949 | |b 32046819636528|c SYSANFI|d 338.7 CARRE|l OBR|n 7275849|o 1|s l|w 01/02/2020|x 9|y PBK | ||
| 949 | |b 32046819636544|c SYSANFI|d 338.7 CARRE|l OBR|n 7275851|o 0|s i|w 01/02/2020|x 6|y PBK | ||
| 949 | |b 32046817612174|c SYSANFI|d 338.7 CARRE|l RBH|n 6981361|o 0|s i|w 03/22/2019|x 23|y BK | ||
| 949 | |b 32046815617050|c SYSANFI|d 338.7 CARRE|l RBH|n 6672675|o 0|s i|w 05/25/2018|x 34|y BK | ||
| 949 | |b 32046819636494|c SYSANFI|d 338.7 CARRE|l WRL|n 7275846|o 0|s o|w 01/02/2020|x 10|y PBK | ||
| 949 | |b 32046819636379|c SYSANFI|d 338.7 CARRE|l WRL|n 7275834|o 0|s i|w 01/02/2020|x 11|y PBK | ||
| 999 | |a 729505 | ||
